Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells

Neural cell adhesion molecule 1 (NCAM1), synaptophysin (SYPT), and chromogranin A (CGA) are immunohistochemical markers for diagnosing lung neuroendocrine tumors (LNETs). However, the precise expression mechanisms have not been studied in enough detail. The purpose of the present study is to define the molecular mechanisms of NCAM1, SYPT, and CGA gene expressions, using cultivated lung cancer cells and focusing upon NeuroD1 (ND1), achaete‐scute homolog‐like 1 (ASCL1), and known transcription factors, repressor element 1 (RE1)‐silencing transcription factor (REST) and c‐AMP responsive element‐binding protein (CREB). Promoter assays, chromatin immunoprecipitation, and transfection experiments revealed that ND1 activated NCAM1, that ASCL1 weakly upregulated SYPT expression, and that CGA expression was not regulated by ND1 or ASCL1. REST expression was restricted in non‐small cell lung cancer (NSCLC) cells, and knockdown of REST could cause as much SYPT expression as in SCLC cells and weak CGA expression in NSCLC cells. However, CGA gene upregulation via CREB activation was not found in REST‐lacking NSCLC cells, indicating the requirement of some additional mechanism for sufficient expression. These results suggest that NCAM1, SYPT and CGA expressions are differently regulated by neuroendocrine phenotype‐specific transcription factors and provide a reason why NCAM1 and SYPT are frequently expressed in LNETs, irrespective of malignancy grade.

[1]  François Guillemot,et al.  Proneural genes and the specification of neural cell types , 2002, Nature Reviews Neuroscience.

[2]  G. Edelman,et al.  Binding and activation of the promoter for the neural cell adhesion molecule by Pax-8. , 1994, The Journal of biological chemistry.

[3]  E. Tartour,et al.  [Neuroendocrine tumors]. , 1992, La Revue du praticien.

[4]  M. Sheppard,et al.  Small Cell Lung Carcinoma (SCLC): A Clinicopathologic Study of 100 Cases With Surgical Specimens , 2002, The American journal of surgical pathology.

[5]  B. Cruickshank,et al.  The Carcinoid Tumour , 1949, Edinburgh medical journal.

[6]  G. Mandel,et al.  REST and Its Corepressors Mediate Plasticity of Neuronal Gene Chromatin throughout Neurogenesis , 2005, Cell.

[7]  G. Edelman,et al.  Cell adhesion molecules as targets for Hox genes: neural cell adhesion molecule promoter activity is modulated by cotransfection with Hox-2.5 and -2.4. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Takehiko Fujisawa,et al.  Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis , 2006, Modern Pathology.

[9]  J. Tomashefski,et al.  Dail and Hammar's pulmonary pathology , 2008 .

[10]  R. Wood‐Baker,et al.  Nonsmall Cell Lung Carcinoma With Neuroendocrine Differentiation—An Entity of No Clinical or Prognostic Significance , 2007, The American journal of surgical pathology.

[11]  C. Becker,et al.  Relaxation of glycine receptor and onconeural gene transcription control in NRSF deficient small cell lung cancer cell lines. , 2004, Brain research. Molecular brain research.

[12]  Berthold Göttgens,et al.  Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  X. Bertagna,et al.  RT-PCR analysis of corticotroph-associated genes expression in carcinoid tumours in the ectopic-ACTH syndrome. , 2006, European journal of endocrinology.

[14]  A. Ernst,et al.  Small Cell Carcinoma , 2010 .

[15]  S. Baylin,et al.  Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Kageyama,et al.  Helix-loop-helix factors in growth and differentiation of the vertebrate nervous system. , 1997, Current opinion in genetics & development.

[17]  M. Chou,et al.  Small cell lung carcinoma: Clinicopathological, immunohistochemical, and ultrastructural study , 1990, Journal of surgical oncology.

[18]  Takashi Takahashi,et al.  Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer. , 2009, The American journal of pathology.

[19]  Y Iwasaki,et al.  [Large cell carcinoma]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[20]  E. Huang,et al.  NeuroD-null mice are deaf due to a severe loss of the inner ear sensory neurons during development. , 2001, Development.

[21]  R. Liem,et al.  RE1 silencing transcription factor is involved in regulating neuron‐specific expression of α‐internexin and neurofilament genes , 2009, Journal of neurochemistry.

[22]  T. Miyata,et al.  NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. , 1999, Genes & development.

[23]  H. Weintraub,et al.  Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. , 1995, Science.

[24]  J. Coulson,et al.  SCG3 Transcript in Peripheral Blood Is a Prognostic Biomarker for REST-Deficient Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[25]  U Schumacher,et al.  Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer , 2010, Oncogene.

[26]  Takaaki Ito,et al.  Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. , 2002, The American journal of pathology.

[27]  Gail Mandel,et al.  REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons , 1995, Cell.

[28]  H. Dietz,et al.  Targeted Disruption of NeuroD, a Proneural Basic Helix-Loop-Helix Factor, Impairs Distal Lung Formation and Neuroendocrine Morphology in the Neonatal Lung , 2008, Journal of Biological Chemistry.

[29]  A. Gazdar,et al.  A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. , 1990, Cancer research.

[30]  A. Joliot,et al.  An upstream regulatory element of the NCAM promoter contains a binding site for homeodomains , 1991, FEBS letters.

[31]  C. Becker,et al.  Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells , 2003, Oncogene.

[32]  David J. Anderson,et al.  Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors , 1990, Nature.

[33]  J. Quinn,et al.  A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. , 2000, Cancer research.

[34]  D. Anderson,et al.  Identification of potential target genes for the neuron-restrictive silencer factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Dingledine,et al.  Neurological disease: listening to gene silencers. , 2001, Molecular interventions.

[36]  M. Tsai,et al.  BETA2 and pancreatic islet development. , 2001, Recent progress in hormone research.

[37]  E. Miska,et al.  The Co-repressor mSin3A Is a Functional Component of the REST-CoREST Repressor Complex* , 2000, The Journal of Biological Chemistry.

[38]  C. Cepko,et al.  NeuroD regulates multiple functions in the developing neural retina in rodent. , 1999, Development.

[39]  H. Asamura,et al.  hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors , 2004, Modern Pathology.

[40]  M. Hohl,et al.  RE-1 silencing transcription factor (REST) regulates human synaptophysin gene transcription through an intronic sequence-specific DNA-binding site. , 2002, European journal of biochemistry.

[41]  F. Walsh,et al.  Characterization of the human N-CAM promoter. , 1990, The Biochemical journal.

[42]  X. Teng.  [World Health Organization classification of tumours, pathology and genetics of tumours of the lung]. , 2005, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[43]  R. Rehfuss,et al.  Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene. , 1998, Endocrinology.

[44]  M. Tsai,et al.  The basic helix-loop-helix transcription factor BETA2/NeuroD is expressed in mammalian enteroendocrine cells and activates secretin gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Kageyama,et al.  Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. , 2000, Development.

[46]  Yang Shi,et al.  SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation , 2008, Nature.

[47]  Shuta Tomida,et al.  Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. , 2008, Cancer research.

[48]  S. Yagishita,et al.  An Ultrastructural Study , 1979 .

[49]  E. Brambilla,et al.  Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. , 1998, The American journal of surgical pathology.

[50]  D J Anderson,et al.  The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes , 1995, Science.

[51]  C. Murre,et al.  The cellular Pax-Hox-helix connection. , 2003, Biochimica et biophysica acta.

[52]  C. Schubiger,et al.  [Neuroendocrine carcinoma]. , 2020, Schweizerische medizinische Wochenschrift.

[53]  Eugene Bolotin,et al.  Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. , 2007, Gene.

[54]  H. Satoh,et al.  Lack of class II transactivator causes severe deficiency of HLA‐DR expression in small cell lung cancer , 1999, The Journal of pathology.

[55]  M. Tsai,et al.  Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. , 1997, Genes & development.

[56]  G. Edelman,et al.  Binding and transcriptional activation of the promoter for the neural cell adhesion molecule by HoxC6 (Hox-3.3). , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Steinshamn,et al.  Expression of neuroendocrine markers in non‐small cell lung cancer , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[58]  V. Ananthanarayanan,et al.  Large Cell Neuroendocrine Carcinoma , 2017 .